Castle Biosciences (CSTL) Could Be 23% Undervalued Following Fresh Melanoma Data
Castle Biosciences (CSTL) just put fresh clinical data for its DecisionDx-Melanoma test on stage at the EADV Congress 2026, giving investors new detail on risk stratification in cutaneous melanoma care.
Recent trading has been choppy for Castle Biosciences, with the share price gaining 2.15% over the last day but easing 4.38% over the past week. At the same time, the 90-day share price return of 42.12% and 1-year total shareholder return of 42.48% point to momentum building around the story as clinical data like the EADV results sharpen views on both growth potential and risk in the melanoma testing franchise.
Scan how Castle Biosciences fits into a wider play on precision diagnostics by comparing it with 32 healthcare AI stocks targeting data-driven decision tools in specialist care.
Bulls point to Castle Biosciences’ melanoma data and recent share price momentum. Bears focus on ongoing losses and past drawdowns. Which side does the current valuation support as you weigh the risk and reward?
Most Popular Narrative: 23% Undervalued
Castle Biosciences last closed at $33.71, while the most followed narrative anchors fair value at $44.00. This puts the spotlight on whether current enthusiasm for its test portfolio lines up with that implied upside.
Castle's rapid expansion of its test menu, especially into high-growth, underpenetrated indications like gastrointestinal diagnostics (TissueCypher) and new pipeline areas such as atopic dermatitis, positions the company to tap into substantially larger patient populations and diversify revenue streams, directly supporting long-term revenue growth.
The ongoing shift toward precision and individualized medicine across healthcare systems, combined with Castle's robust real-world evidence (e.g., NCI SEER study showing 32% reduction in melanoma mortality), sets the stage for broader clinical adoption and increased commercial and payer demand, likely boosting test volumes and supporting higher revenues.
See why 4 investors see Castle Biosciences as 23% undervalued.
Result: Fair Value of $44.00 (UNDERVALUED)
Still, reimbursement setbacks for tests like DecisionDx SCC and the risk of slower payer coverage across Castle Biosciences’ portfolio could quickly challenge that 23% undervalued view.
Find out about the key risks to this Castle Biosciences narrative.
Next Steps
Mixed views run through this Castle Biosciences story, so weigh the clinical momentum against the open questions on risk and reward by reviewing the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Castle Biosciences?
If Castle Biosciences has sharpened your interest in focused opportunities, do not stop here. Use trusted tools to uncover other clear, data driven ideas worth your attention.
- Target stronger entry points by scanning companies that score well on quality and valuation through the 27 high quality undervalued stocks.
- Prioritise capital preservation first and shortlist steadier opportunities using the 31 resilient stocks with low risk scores.
- Hunt for lesser known prospects with solid fundamentals by reviewing the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com